Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MMP2-IN-1 通过阻滞细胞周期和诱导细胞凋亡,在部分癌细胞中显示出显着的抗增殖活性。MMP2-IN-1 是MMP2 的中度强效抑制剂 (IC50 = 6.8 μM)。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 987 | 5日内发货 | ||
5 mg | ¥ 1,980 | 5日内发货 | ||
25 mg | ¥ 6,740 | 6-8周 | ||
50 mg | ¥ 8,760 | 6-8周 | ||
100 mg | ¥ 13,500 | 6-8周 |
产品描述 | MMP2-IN-1 shows siganificant antiproliferative activity in certain cancer cells through arresting the cell cycle and inducing apoptosis. MMP2-IN-1 is a moderate potenet inhibitor of MMP2 (IC 50 = 6.8 μM)[1]. |
体外活性 | MMP2-IN-1 (compound 4a) (0-10 μM; 74 hours) exhibits IC 50 values of 0.07 μM, 0.11 μM, and 0.18 μM against MDA-MB-231, A549, and HeLa cancer cells, respectively, and over 10 μM in Hep 5G cells [1]. MMP2-IN-1 (10 μM; 24 hours) induces cell cycle arrest in the S phase [1]. MMP2-IN-1 (0.01 μM, 0.1 μM, 1 μM and 10 μM; 24 hours) induces a dose-dependent increment in early-and late-stage apoptosis of MDA-MB-231 cells, and increased the early-stage apoptosis percentage from 4.66% to 10.9% at 10 μM [1]. Cell Proliferation Assay Cell Line: MDA-MB-231, A549, HeLa and Hep 5G cells [1] Concentration: 0-10 μM Incubation Time: 74 hours Result: Exhibited IC 50 values of 0.07 μM, 0.11 μM, and 0.18 μM against MDA-MB-231, A549, and HeLa cancer cells, respectively, and over 10 μM in Hep 5G cells. Cell Cycle Analysis Cell Line: MDA-MB-231 [1] Concentration: 10 μM Incubation Time: 24 hours Result: Induced cell cycle arrest in the S phase. Apoptosis Analysis Cell Line: MDA-MB-231 [1] Concentration: 0.01 μM, 0.1 μM, 1 μM and 10 μM Incubation Time: 24 hours Result: Induced a dose-dependent increment in early-and late-stage apoptosis of MDA-MB-231 cells, and increased the early-stage apoptosis percentage from 4.66% to 10.9% at 10 μM. |
体内活性 | MMP2-IN-1 (100 mg/kg, 150 mg/kg, 200 mg/kg, 250 mg/kg; IP, single) causes 0%, 30%, 50% and 60% mortality rate at dosing 100 mg/kg, 150 mg/kg, 200 mg/kg and 250 mg/kg respectively [1]. MMP2-IN-1 (10 mg/kg; IP, daily, for 14 days) significantly inhibits tumor growth in metastatic 4T1 murine breast cancer model [1]. Animal Model: Kunming mice (n = 10, half male and half female) [1] Dosage: 100 mg/kg, 150 mg/kg, 200 mg/kg, 250 mg/kg Administration: IP, single Result: No mortality occurred after administration of 100 mg/kg, and the mortality rate was 30%, 50% and 60% at dosing 150 mg/kg, 200 mg/kg, 250 mg/kg respectively. Animal Model: Orthotopic 4T1 tumor-bearing mice [1] Dosage: 10 mg/kg Administration: IP, daily, for 14 days Result: Significantly inhibited tumor growth in metastatic 4T1 murine breast cancer model. |
分子量 | 319.33 |
分子式 | C15H13NO5S |
CAS No. | 2764598-01-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
MMP2-IN-1 2764598-01-6 Inhibitor inhibitor inhibit